Dr. Melanie Rolli shares her thoughts on what Helsinn has achieved in the first half of the year. #ceotalks
Today, I am excited to share with you some important achievements at the Helsinn Group in the first half of 2024. - As partner of choice, we have successfully renewed distribution and licensing agreements with some of our long-standing partners. - In the US, we launched AKYNZEO® (fosnetupitant/palonosetron) in a ready-to-use vial, providing new preparation and administration features. - Commercial supplies exceeded expectations and were delivered on time confirming the high performance track record of our manufacturing site HBP - For the fourth consecutive year we achieved carbon neutrality, we have continued our efforts in ESG practices completing the sustainability report for 2023 full year, and we have actively promoted local CSR initiatives. Our global team delivered these results with expertise, commitment and passion: I am proud of our achievements and confident in our ongoing transformational journey. #business #pharma